US FDA approves Mirum Pharma's genetic disorder drug-March 2024-www.financetom.com

US FDA approves Mirum Pharma's genetic disorder drug

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA approves Mirum Pharma's genetic disorder drug

Feb 21, 2025 9:18 AM

Feb 21 (Reuters) - The U.S. Food and Drug Administration

said on Friday it has approved Mirum Pharmaceuticals' ( MIRM )

drug to treat a type of rare disorder, which affects the body's

ability to metabolize fats known as cholesterol.

Previous page： --Sprinklr Guides For Q1 EPS of $0.07 on Revenue of $194-$195 Million, vs CIQ Analyst Consensus of $0.09/Share on Revenue of $193 Million Next page： Johnson & Johnson Strong Strategic Fit For Shockwave Medical, But Medtronic, Boston Scientific Could Be Other Bidder, Says Analyst

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

--Sprinklr Guides For Q1 EPS of $0.07 on Revenue of $194-$195 Million, vs CIQ Analyst Consensus of $0.09/Share on Revenue of $193 Million

Mar 27, 2024

04:14 PM EDT, 03/27/2024 (MT Newswires) -- Price: 13.03, Change: +0.02, Percent Change: +0.19 ...

Johnson & Johnson Strong Strategic Fit For Shockwave Medical, But Medtronic, Boston Scientific Could Be Other Bidder, Says Analyst

Mar 27, 2024

Tuesday, Shockwave Medical Inc ( SWAV ) shares traded higher following a Wall Street Journal report suggesting Johnson & Johnson ( JNJ ) is reportedly in talks to acquire the company. Shockwave Medical ( SWAV ) is a cardiovascular medical device. In 2022, Johnson & Johnson ( JNJ ) acquired heart failure device-focused Abiomed Inc. for an upfront payment of $380.00 per share in cash, corresponding to...

Braze Fiscal Q4 Non-GAAP Loss Narrows, Revenue Rises; Fiscal Q1, 2025 Outlook Set

Mar 27, 2024

04:37 PM EDT, 03/27/2024 (MT Newswires) -- Braze (BRZE) reported a fiscal Q4 non-GAAP net loss late Wednesday of $0.04 per diluted share, compared with a net loss of $0.14 a year earlier. Analysts polled by Capital IQ expected a loss of $0.05. Revenue for the quarter that ended Jan. 31 was $131 million, up from $98.7 million a year...

The Westaim Corporation Reports Q4 And Full Year 2023 Results

Mar 27, 2024

04:43 PM EDT, 03/27/2024 (MT Newswires) -- The Westaim Corporation ( WEDXF ) Wednesday announced its audited financial results for the quarter and full year ending Dec. 31, 2023. Westaim ( WEDXF ) recorded a net profit of US$35.1 million (US$0.26 diluted earnings per share) for Q4 2023 compared to a net profit of US$32.8 million (US$0.23 diluted earnings per...